Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control.

ABSTRACT: Diabetes affects almost half a billion people, and all individuals with type 1 diabetes (T1D) and a large portion of individuals with type 2 diabetes rely on self-administration of the peptide hormone insulin to achieve glucose control. However, this treatment modality has cumbersome storage and equipment requirements and is susceptible to fatal user error. Here, reasoning that a cell-based therapy could be coupled to an external induction circuit for blood glucose control, as a proof of concept we developed far-red light (FRL)-activated human islet-like designer (FAID) cells and demonstrated how FAID cell implants achieved safe and sustained glucose control in diabetic model mice. Specifically, by introducing a FRL-triggered optogenetic device into human mesenchymal stem cells (hMSCs), wh

SUBMITTER: Yu G 

PROVIDER: S-EPMC8753431 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature